Research Article Volume 01, Issue No. 02. 2025

The Medical Journal of Clinical Pathology and Microbiology



Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology

[1] Joseph, [1] Fitri

[1] Faculty of Medicine, Maranatha Christian University, Bandung City, West Java, Indonesia

Correspondence : dr.joseph98973@gmail.com

Article History :

Received date : 2024/07/15
Revised date : 2024/08/09
Accepted date : 2024/09/22
Published date : 2025/01/12

Copyright: *© 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (https://creativecommons.org/licenses/by-nc/4.0/).*

ABSTRACT

Background: The diagnostic value of cerebrospinal fluid neurofilament light protein (NfL) in neurology is increasingly recognized as a significant area of research, particularly concerning its role as a biomarker for various neurodegenerative disorders. The literature consistently demonstrates that elevated NfL levels in cerebrospinal fluid (CSF) correlate with disease severity and progression in conditions such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and frontotemporal dementia (FTD). **Literature Review:** The foundational study by (Gagliardi et al., 2019) established NfL as a sensitive marker for axonal degeneration, revealing a direct correlation between elevated NfL levels and diagnostic delays in ALS patients. This was further supported by (M. Forgrave et al., 2019), who highlighted methodological discrepancies in NfL quantification across studies, emphasizing the need for standardized assays to enhance diagnostic reliability. Their systematic review affirmed that while NfL is effective in distinguishing AD from healthy controls, its performance in differentiating AD from mild cognitive impairment (MCI) is less robust. In a broader context, (Delaby et al., 2020) confirmed that increased NfL levels are indicative of clinical severity across multiple neurodegenerative diseases, reinforcing the potential of NfL as a biomarker for early diagnosis and monitoring progression. **Conclusion:** In conclusion, the body of literature collectively underscores the diagnostic value of cerebrospinal fluid neurofilament light protein (NfL) in neurology, establishing it as a crucial biomarker for neurodegenerative diseases. The evidence highlights NfL's potential for early diagnosis, monitoring disease progression, and improving clinical decision-making. However, standardization of measurement techniques and a comprehensive understanding of NfL's limitations are essential for its effective application in clinical settings.

Keyword: Diagnostic Value, Cerebrospinal Fluid Neurofilament Light Protein, Neurology

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

INTRODUCTION

The diagnostic value of cerebrospinal fluid neurofilament light protein (NfL) in neurology has garnered significant attention in recent years, particularly for its potential as a biomarker in various neurodegenerative disorders. The literature reveals a growing consensus on the utility of NfL in diagnosing and monitoring conditions such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and frontotemporal dementia (FTD).

In 2019, (Gagliardi et al., 2019) demonstrated that NfL is the most abundant neurofilament subunit in axons and is rapidly detectable in cerebrospinal fluid (CSF) following axonal degeneration. Their findings indicated that elevated CSF NfL concentrations correlate significantly with diagnostic delays and disease progression in ALS patients. This study established a critical link between NfL levels and the extent of motor neuron degeneration, reinforcing its role as a sensitive diagnostic marker.

Building on this foundation, (M. Forgrave et al., 2019) conducted a systematic review and meta-analysis that quantitatively assessed the diagnostic performance of NfL across various neurodegenerative diseases. They highlighted the methodological discrepancies in NfL quantification, which could impact the comparability of results across studies. The review suggested that while NfL levels in CSF could effectively distinguish AD from healthy controls, its utility in differentiating between AD and mild cognitive impairment (MCI) remains limited. This finding underscores the need for standardized assay methods to enhance the reliability of NfL as a diagnostic tool.

In a 2020 study, (Delaby et al., 2020) expanded the discussion by examining NfL levels across a broader spectrum of neurodegenerative disorders. They confirmed that increased CSF NfL levels correlate with clinical severity and progression in conditions such as AD, FTD, and ALS. Their work further established NfL as a

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

promising biomarker for evaluating neurodegenerative processes, emphasizing its potential for early diagnosis and monitoring of disease progression.

(Gaetani et al., 2021) added a novel perspective by exploring the role of NfL in the presymptomatic phase of neurological diseases. They posited that NfL could serve as a valuable biomarker for detecting early axonal damage, thereby facilitating timely interventions in at-risk populations. This highlights the potential of NfL not only as a diagnostic marker but also as a tool for predicting disease onset.

Finally, (Kartau et al., 2023) investigated the relationship between NfL levels and cognitive and motor performance, further validating its significance as a biomarker. Their research indicated that elevated NfL levels are associated with brain atrophy and cognitive decline across various neurological conditions, reinforcing its role in understanding disease impact on functional outcomes.

Together, these studies articulate a compelling narrative regarding the diagnostic value of cerebrospinal fluid neurofilament light protein in neurology, underscoring its relevance as a biomarker for neurodegenerative diseases and paving the way for future research and clinical applications.

LITERATURE REVIEW

The article "Diagnostic and Prognostic Role of Blood and Cerebrospinal Fluid and Blood Neurofilaments in Amyotrophic Lateral Sclerosis: A Review of the Literature" provides a comprehensive overview of the significance of neurofilament light protein (NfL) in the context of amyotrophic lateral sclerosis (ALS). The authors emphasize NfL as a pivotal biomarker for diagnosing motor neuron diseases (MND), particularly ALS, due to its rapid detectability in biofluids following axonal degeneration.

A critical aspect of the article is the assertion that NfL levels in cerebrospinal fluid (CSF) can serve as a sensitive indicator for distinguishing ALS patients from those with other conditions, such as diabetic neuropathy (DM). This differentiation is crucial, as it underscores the potential of NfL to aid in clinical decision-making

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

regarding the diagnosis of MND. The authors report findings from Lu et al. that indicate significantly higher NfL levels in ALS patients compared to controls, which correlates with disease progression and survival rates. Such correlations highlight the utility of NfL not merely as a diagnostic marker but also as a prognostic tool, which can provide insights into the severity and trajectory of the disease.

However, the article also cautions that NfL is an unspecific marker of axonal damage, suggesting that its diagnostic utility should be complemented by additional assessments. This point is critical, as it indicates the necessity for a multifaceted approach in diagnosing and monitoring ALS.

Moreover, the article discusses the relationship between CSF NfL concentrations and neuroimaging findings, such as fractional anisotropy and radial diffusivity, which further elucidates the neurochemical landscape of ALS. This integration of biochemical and neuroimaging data offers a more holistic view of neurodegeneration, suggesting that a combined approach could enhance diagnostic accuracy and patient management.

The article titled "The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis" provides a comprehensive evaluation of neurofilament light chain (NfL) as a biomarker for neurodegenerative diseases, specifically focusing on its diagnostic utility in cerebrospinal fluid (CSF) and blood.

The systematic review and meta-analysis present a quantitative assessment of NfL's performance across various neurodegenerative conditions, including Alzheimer's disease (AD), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS). The authors highlight that standard enzyme-linked immunosorbent assays (ELISAs) have been predominantly utilized for quantifying NfL in CSF, while more advanced methodologies such as array-based digital ELISA and electrochemiluminescence (ECL) assays are favored for blood samples due to their

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

superior analytical sensitivity. This distinction is critical, as the choice of methodology significantly influences the reliability and comparability of NfL measurements.

One of the key findings from the meta-analysis is the pronounced elevation of CSF NfL concentrations in AD patients compared to cognitively unimpaired controls, approximately doubling the levels. This suggests a robust diagnostic potential for CSF NfL in distinguishing AD from healthy individuals. However, the authors note that the diagnostic performance diminishes when comparing AD with mild cognitive impairment (MCI) and other disease mimics, such as vascular dementia and Lewy body dementia. The modest increase in NfL levels in AD relative to MCI indicates limitations in its utility for early diagnosis or differentiation from other neurodegenerative disorders.

Furthermore, the article underscores the challenges posed by methodological discrepancies across studies. The authors report instances of misreported units for NfL, which complicates direct comparisons and highlights the necessity for assay harmonization to improve diagnostic accuracy.

The article "Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders" provides a comprehensive examination of the diagnostic value of Neurofilament Light (NfL) protein in cerebrospinal fluid (CSF) across various neurodegenerative conditions. The authors underscore the significance of NfL as a biomarker, particularly its expression in myelinated axons and its secretion into CSF, albeit in small quantities. This aspect is crucial, as it establishes the foundation for understanding the relationship between NfL levels and neuro-axonal damage, which is a common feature across numerous neurological disorders.

The study highlights how disruptions in neurofilament organization are indicative of several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), frontotemporal dementia (FTD), and vascular dementia. The authors provide evidence that elevated CSF NfL levels correlate with

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

clinical progression and severity of these disorders. This correlation is particularly evident in ALS, where NfL levels not only reflect the extent of neuro-axonal damage but also serve as a potential prognostic indicator for disease progression.

Furthermore, the research presented in this article emphasizes the utility of CSF NfL in the evaluation and monitoring of patients with cognitive impairments. The findings indicate that patients diagnosed with mild cognitive impairment (MCI), AD, FTD, or ALS exhibit significantly higher CSF NfL levels compared to control subjects. This observation supports the notion that NfL could be a valuable biomarker for early diagnosis and ongoing assessment of neurodegenerative diseases.

The study's investigation within the SPIN cohort, which encompasses a diverse range of neurodegenerative disorders, strengthens the argument for the role of CSF NfL in clinical practice. The authors specifically point out the potential of CSF NfL for the early diagnosis and follow-up of patients with dementia with Lewy bodies (DLB), further illustrating its broad applicability across different conditions.

The article "Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain" provides a comprehensive examination of neurofilament light chain (NfL) as a biomarker for axonal damage in neurological diseases. The authors argue that the measurement of NfL in cerebrospinal fluid (CSF) and blood not only serves as a reliable indicator of axonal injury but also functions as an early warning system for the presence of central nervous system (CNS) diseases prior to clinical manifestation.

One of the key strengths of the article lies in its detailed discussion of the properties that make NfL an ideal biomarker. The authors emphasize that NfL must be easily measurable, sensitive, reliable, and reproducible. They highlight the correlation between NfL concentrations in CSF and blood, asserting that this relationship enhances the biomarker's utility across various clinical settings. The article details the current methodologies for measuring NfL, including enzyme-linked

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

immunosorbent assays (ELISA) and emerging ultrasensitive techniques, which are crucial for advancing the clinical application of NfL measurements.

Furthermore, the authors present compelling evidence that NfL levels correlate with the severity of neurological diseases and can predict clinical outcomes. This predictive capacity is particularly significant, as it underscores the potential for NfL to inform early therapeutic interventions, thereby expanding treatment opportunities for patients diagnosed in the presymptomatic phase. The article effectively synthesizes findings from various studies, demonstrating that blood NfL levels can trace the progression of different CNS disorders, which may lead to improved patient management strategies.

However, while the article provides a thorough overview of the potential of NfL as a biomarker, it could benefit from a more critical discussion of the limitations and challenges associated with its clinical implementation. For instance, the variability in NfL levels due to factors such as age, sex, and comorbidities may complicate the interpretation of results. Additionally, the authors could explore the ethical implications of presymptomatic testing and the psychological impact on patients who may learn of their risk for developing neurological diseases.

The article "Neurofilament light level correlates with brain atrophy, and cognitive and motor performance" provides significant insights into the role of neurofilament light (NfL) protein as a biomarker in various neurological conditions. The authors emphasize that NfL, a polypeptide expressed exclusively in neurons, is released into cerebrospinal fluid (CSF) following axonal injury, making it a valuable indicator of neuronal health and disease progression.

One of the key findings highlighted in the article is the correlation between elevated NfL levels and various neurological disorders, including Alzheimer’s disease (AD), motor neuron disease (MND), and multiple sclerosis (MS). The authors present compelling evidence supporting the utility of NfL in the differential diagnosis and prognosis of amyotrophic lateral sclerosis (ALS), indicating that NfL can effectively differentiate between clinical and genetic subgroups of ALS. This

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

specificity is critical for tailoring treatment strategies and improving patient outcomes.

Moreover, the article discusses the dynamic nature of NfL as a biomarker, suggesting its potential application in monitoring disease activity and treatment response in MS. The authors explore the association between NfL levels and cognitive impairment across several neurological diseases. Their findings indicate an inverse relationship between general cognitive status and NfL levels, underscoring the relevance of NfL in assessing cognitive decline.

The study's focus on the relationship between CSF NfL levels and structural brain changes, specifically white matter hyperintensities (WMH) and brain volumes, adds depth to the understanding of NfL as a marker of axonal injury. By examining its correlation with cognitive domains such as processing speed, executive function, and memory, the authors provide a comprehensive view of how NfL can serve as a multifaceted tool in clinical practice.

CONCLUSION

The diagnostic value of cerebrospinal fluid neurofilament light protein (NfL) in neurology is increasingly recognized as a significant area of research, particularly concerning its role as a biomarker for various neurodegenerative disorders. The literature consistently demonstrates that elevated NfL levels in cerebrospinal fluid (CSF) correlate with disease severity and progression in conditions such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and frontotemporal dementia (FTD).

The foundational study by (Gagliardi et al., 2019) established NfL as a sensitive marker for axonal degeneration, revealing a direct correlation between elevated NfL levels and diagnostic delays in ALS patients. This was further supported by (M. Forgrave et al., 2019), who highlighted methodological discrepancies in NfL quantification across studies, emphasizing the need for standardized assays to enhance diagnostic reliability. Their systematic review affirmed that while NfL is

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

effective in distinguishing AD from healthy controls, its performance in differentiating AD from mild cognitive impairment (MCI) is less robust.

In a broader context, (Delaby et al., 2020) confirmed that increased NfL levels are indicative of clinical severity across multiple neurodegenerative diseases, reinforcing the potential of NfL as a biomarker for early diagnosis and monitoring progression. The exploration of NfL's role in the presymptomatic phase of neurological diseases by (Gaetani et al., 2021) further underscores its utility in detecting early axonal damage, which could facilitate timely interventions.

Moreover, (Kartau et al., 2023) provided insights into the relationship between NfL levels and cognitive and motor performance, validating its significance as a biomarker associated with brain atrophy and cognitive decline. This multifaceted approach to understanding NfL's diagnostic capabilities illustrates its relevance not only in diagnosing neurodegenerative diseases but also in monitoring their progression and impact on functional outcomes.

In conclusion, the body of literature collectively underscores the diagnostic value of cerebrospinal fluid neurofilament light protein (NfL) in neurology, establishing it as a crucial biomarker for neurodegenerative diseases. The evidence highlights NfL's potential for early diagnosis, monitoring disease progression, and improving clinical decision-making. However, standardization of measurement techniques and a comprehensive understanding of NfL's limitations are essential for its effective application in clinical settings.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

REFERENCES

- Gagliardi, D., Meneri, M., Saccomanno, D., Bresolin, N., Pietro Comi, G., & Corti, S., 2019. Diagnostic and Prognostic Role of Blood and Cerebrospinal Fluid and Blood Neurofilaments in Amyotrophic Lateral Sclerosis: A Review of the Literature. ncbi.nlm.nih.gov
- M. Forgrave, L., Ma, M., R. Best, J., & L. DeMarco, M., 2019. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. ncbi.nlm.nih.gov
- Delaby, C., Alcolea, D., Carmona-Iragui, M., Illán-Gala, I., Morenas-Rodríguez, E., Barroeta, I., Altuna, M., Estellés, T., Santos-Santos, M., Turon-Sans, J., Muñoz, L., Ribosa-Nogué, R., Sala-Matavera, I., Sánchez-Saudinos, B., Subirana, A., Videla, L., Benejam, B., Sirisi, S., Lehmann, S., Belbin, O., Clarimon, J., Blesa, R., Pagonabarraga, J., Rojas-Garcia, R., Fortea, J., & Lleó, A., 2020. Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. ncbi.nlm.nih.gov
- Gaetani, L., Parnetti, L., Calabresi, P., & Di Filippo, M., 2021. Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain. ncbi.nlm.nih.gov
- Kartau, M., Melkas, S., Kartau, J., Arola, A., Laakso, H., Pitkänen, J., Lempiäinen, J., Koikkalainen, J., Lötjönen, J., Korvenoja, A., Ahlström, M., Herukka, S. K., Erkinjuntti, T., & Jokinen, H., 2023. Neurofilament light level correlates with brain atrophy, and cognitive and motor performance. ncbi.nlm.nih.gov

Downloaded from The Medical Journal of Clinical Pathology and Microbiology
Copyright © International Medical Journal Corp. Ltd. All rights reserved